Stem Cells SpinWAR:SCS 25 Days Payable is 2,555.00 as of Mar. 2026, which is 25% above its 10-year median of 2,046.61. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Stem Cells Spin ranks better than 82.48% on this metric.
The historical rank and industry rank for Stem Cells Spin's Days Payable or its related term are showing as below:
WAR:SCS'
s Days Payable Range Over the Past 10 Years
Min: 377.3 Med: 2046.61 Max: 6305.38
Current: 657
During the past 13 years, Stem Cells Spin's highest Days Payable was 6305.38. The lowest was 377.30. And the median was 2046.61.
WAR:SCS's Days Payable is ranked better than 82.48% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs WAR:SCS: 657.00
Stem Cells Spin's Days Payable
declined
from Mar. 2025 (3,239.38) to Mar. 2026 (2,555.00).
It may suggest that Stem Cells Spinaccelerated paying its suppliers.
Stem Cells Spin Days Payable Related Terms
Stem Cells Spin Days Payable Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Stem Cells Spin's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Days Payable distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Stem Cells Spin's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a Days Payable of 2,555.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Stem Cells Spin and its competitors. This is 25% above median its historical median of 2,046.61. Over the past decade, Stem Cells Spin's Days Payable has ranged from 377.30 to 6,305.38. According to the industry distribution chart, Stem Cells Spin ranks #123 out of 702 companies in the Biotechnology industry, placing it in the top 17.5%.
Is Stem Cells Spin's Days Payable too high?
Stem Cells Spin's current Days Payable of 2,555.00 is 25% above median its 10-year median of 2,046.61. Over the past 10 years, this metric has ranged from a low of 377.30 to a high of 6,305.38. The Biotechnology industry median Days Payable is 113.56. Stem Cells Spin's value of 2,555.00 is 2149.9% above this industry median. Based on the distribution chart, Stem Cells Spin ranks #123 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #123 out of 702 companies for Days Payable. This places Stem Cells Spin in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Stem Cells Spin's value of 2,555.00 is 2149.9% above this benchmark. Historically, Stem Cells Spin's own Days Payable has ranged from 377.30 to 6,305.38 over the past decade. While the company's 10-year median is 2,046.61 vs. the industry median of 113.56, Stem Cells Spin has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current Days Payable of 2,555.00 is 2149.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current Days Payable is 2,555.00, which is 25% above median its own 10-year median of 2,046.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current Days Payable is 2,555.00, which is 25% above median its 10-year median of 2,046.61 and 2149.9% above the Biotechnology industry median of 113.56. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Days Payable is 2,555.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
Days Payable: 2,555.00 (25% above median its 10-year median of 2,046.61)
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
Industry Position: 2149.9% above the Biotechnology median (#123 of 702)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
